home / stock / iphyf / iphyf news

IPHYF News and Press, Innate Pharma - Class A From 11/05/25

Stock Information
Company Name: Innate Pharma - Class A
Stock Symbol: IPHYF
Market: OTC
Website: innate-pharma.com
Menu
IPHYF IPHYF Quote IPHYF Short IPHYF News IPHYF Articles IPHYF Message Board
Get IPHYF Alerts

News, Short Squeeze, Breakout and More Instantly...
IPHYF - Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progr...
IPHYF - Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript

2025-10-28 18:21:51 ET Innate Pharma S.A. (IPHA) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stéphanie Cornen Stephanie Cornen -...

IPHYF - Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation Leading KOL Pierluigi Porcu, M.D., a world expert in T-cell lymphomas, will ...

IPHYF - Innate Pharma S.A. GAAP EPS of -Euro0.25, revenue of Euro4.9M

2025-09-17 14:45:13 ET More on Innate Pharma Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript Innate Pharma S.A. 2025 Q2 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate ...
IPHYF - Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

2025-09-17 11:43:48 ET Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia Quaratino - Executive VP &...

IPHYF - Innate Pharma Reports First Half 2025 Business Update and Financial Results

IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based...

IPHYF - Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25 th edition of the European Midcap E...
IPHYF - Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business ...

IPHYF - Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

IPHYF - Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025

Regulatory news: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Previous 10 Next 10